Browsing by Author Ho, Phoebe (Joy)

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 17 of 17
Issue DateTitleAuthor(s)Citation
2004B7+ T Cells In Myeloma: An Acquired Marker Of Prior Chronic Antigen Presentation.Gibson, John; Ho, Phoebe (Joy); Joshua, Douglas; Sze, Daniel; Brown, Ross; Murray, Allan; Pope, Belinda; Central Clinical School: Medicine; Central Clinical School: Medicine; Central Clinical School: Medicine; PharmacyB7+ T Cells In Myeloma: An Acquired Marker Of Prior Chronic Antigen Presentation., Leukemia & lymphoma, vol.45,(2),2004,pp 363-371
2002The biology and cytogenetics of multiple myelomaGibson, John; Ho, Phoebe (Joy); Joshua, Douglas; Brown, Roderick W.; Campbell, Lynda J.; Central Clinical School: Medicine; Central Clinical School: Medicine; Central Clinical School: MedicineThe biology and cytogenetics of multiple myeloma, Reviews in Clinical and Experimental Hematology, vol.6, 3,pp 276-300
2002Chromosomal and genetic abnormalities in myelomaHo, Phoebe (Joy); Central Clinical School: MedicineChromosomal and genetic abnormalities in myeloma, Clinical and Laboratory Haematology, vol.N/A, N/A,pp 259-269
2011Clinical efficacy and safety evaluation of tailoring iron chelation practice in thalassaemia patients from Asia-Pacific: a subanalysis of the EPIC study of deferasiroxHo, Phoebe (Joy); Bowden, Donald K.; Chan, L; Chiu, C; Domokos, G; Ha, S; Habr, D; Ibrahim, H; Li, C; Lin, K; Roubert, B; Sutcharitchan, Pranee; Viprakasit, V; Xue, H; Central Clinical School: MedicineClinical efficacy and safety evaluation of tailoring iron chelation practice in thalassaemia patients from Asia-Pacific: a subanalysis of the EPIC study of deferasirox, International Journal of Hematology (online), vol.93, 3, 2011,pp 319-328
2001Clonal cytotoxic T cells are expanded in myeloma and reside in the CD8+Cd57+CD28- compartmentBasten, Antony; Baxter, Alan; Fazekas De St Groth, Barbara; Gibson, John; Ho, Phoebe (Joy); Joshua, Douglas; Sze, Daniel; Brown, Roderick W.; Giesajtis,, G; Raitakari, M.; Central Clinical School: Centenary Institute; Central Clinical School: Centenary Institute; Central Clinical School: Centenary Institute; Central Clinical School: Medicine; Central Clinical School: Medicine; Central Clinical School: Medicine; PharmacyClonal cytotoxic T cells are expanded in myeloma and reside in the CD8+Cd57+CD28- compartment, Blood, vol.98,(9),2001,pp 2817-2827
2006Complex phenotypes in the haemoglobinopathies: recommendations on screening and DNA testingGilbert, Anne; Hinchcliffe, Marcus; Ho, Phoebe (Joy); Lammi, Arti; Lindeman, Robert; Trent, Ronald; Webster, Boyd; Blackwell, Jennifer; Bowden, Donald K.; Colley, Alison; Petrou, Vicki; Rowell, John; Saleh, Mona; Wilson, Meredith; Nepean Clinical School: Medicine; Central Clinical School: Medicine; Central Clinical School: Medicine; Central Clinical School: Medicine; Medicine; Central Clinical School: Medicine; MedicineComplex phenotypes in the haemoglobinopathies: recommendations on screening and DNA testing, Pathology 2005, vol.38,(6),2006,pp 507-519
2004Either Interleukin-12 Or Interferon-γ Can Correct The Dendritic Cell Defect Induced By Transforming Growth Factor β₁ In Patients With Myeloma.Gibson, John; Ho, Phoebe (Joy); Joshua, Douglas; Sze, Daniel; Brown, Ross; Hart, Derek; Murray, Allan; Pope, Belinda; Central Clinical School: Medicine; Central Clinical School: Medicine; Central Clinical School: Medicine; PharmacyEither Interleukin-12 Or Interferon-γ Can Correct The Dendritic Cell Defect Induced By Transforming Growth Factor β₁ In Patients With Myeloma., British Journal of Haematology, vol.125,(2),2004,pp 743-748
2004Evolving Transplant Options For Multiple Myeloma: Autologous And Nonmyeloablative Allogenic.Gibson, John; Ho, Phoebe (Joy); Joshua, Douglas; Central Clinical School: Medicine; Central Clinical School: Medicine; Central Clinical School: MedicineEvolving Transplant Options For Multiple Myeloma: Autologous And Nonmyeloablative Allogenic., Transplantation Proceedings 2005, vol.36,(8),2004,pp 2501-2503
2004The Immune System In MyelomaBrown, Richard; Gibson, John; Ho, Phoebe (Joy); Joshua, Douglas; Central Clinical School: Medicine; Central Clinical School: Medicine; Central Clinical School: Medicine; Central Clinical School: MedicineThe Immune System In Myeloma in Multiple myeloma and related disorders, Hodder Arnold, 2004, pp. 29-46-N/A
2013Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balanceBryant, Christian; Fromm, Phillip; Hart, Derek; Ho, Phoebe (Joy); Iland, Harry; Joshua, Douglas; Aklilu, Esther; Brown, Ross; Favaloro, James; Gibson, J; Nassif, N; Suen, Hayley; Woodland, N. B.; Yang, S; Concord Clinical School: ANZAC Research Institute; Concord Clinical School: ANZAC Research Institute; Concord Clinical School: ANZAC Research Institute; Central Clinical School: Medicine; Central Clinical School: Medicine; Central Clinical School: MedicineLong-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance, Blood Cancer Journal, vol.3, N/A, 2013,pp 1-7
2004Low-Grade Lymphoma: The Optimal Timing.Gibson, John; Ho, Phoebe (Joy); Joshua, Douglas; Central Clinical School: Medicine; Central Clinical School: Medicine; Central Clinical School: MedicineLow-Grade Lymphoma: The Optimal Timing., Transplantation Proceedings 2005, vol.36,(7),2004,pp 1995-1998
2003Prediction of high affinity class I-restricted multiple myeloma idiotype peptide epitopesBasten, Antony; Fazekas De St Groth, Barbara; Gibson, John; Ho, Phoebe (Joy); Joshua, Douglas; Sze, Daniel; Brown, Ross D.; Yang, Shihong; Central Clinical School: Centenary Institute; Central Clinical School: Centenary Institute; Central Clinical School: Medicine; Central Clinical School: Medicine; Central Clinical School: Medicine; PharmacyPrediction of high affinity class I-restricted multiple myeloma idiotype peptide epitopes, Leukemia & lymphoma, vol.44,(9),2003,pp 1557-1568
2007Quality of life related to oral versus subcutaneous iron chelation: a time trade-off studyHo, Phoebe (Joy); Joshua, Douglas; Dalton, Andrew; de Abreu Lourenço, Richard; Dowton, David; Houltram, Jennifer; Lindeman, Robert; Osborn, Richard H.; Central Clinical School: Medicine; Central Clinical School: MedicineQuality of life related to oral versus subcutaneous iron chelation: a time trade-off study, Value in Health, vol.10,(6),2007,pp 451-456
2012Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1Allen, John; Al-Shabeeb, Ammira; Ho, Phoebe (Joy); Iland, Harry; Joshua, Douglas; Lau, Edwin; Ling, Silvia; Nikolic, Angela; Catalano, Alberto; Fleming, Shaun; Harrison, Simon James; Horvath, N; Central Clinical School: Centenary Institute; Central Clinical School: Centenary Institute; Central Clinical School: Medicine; Central Clinical School: Medicine; Central Clinical School: Medicine; Central Clinical School: Centenary Institute; Central Clinical School: Centenary Institute; Melanoma FoundationResponse of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1, Haematologica: the hematology journal, vol.97, 1, 2012,pp 64-72
2012Thalidomide consolidation improves progression-free survival in myeloma with normal but not up-regulated expression of fibroblast growth factor receptor 3: analysis from the Australasian Leukaemia and Lymphoma Group MM6 clinical trialBrown, Ross; Gibson, John; Ho, Phoebe (Joy); Joshua, Douglas; Daniher, Daniel; Jeffels, Melinda; Spencer, Andrew; Pharmacy; Central Clinical School: Medicine; Central Clinical School: Medicine; Central Clinical School: MedicineThalidomide consolidation improves progression-free survival in myeloma with normal but not up-regulated expression of fibroblast growth factor receptor 3: analysis from the Australasian Leukaemia and Lymphoma Group MM6 clinical trial, Leukemia and Lymphoma, vol.53, 9, 2012,pp 1728-1734
2004Treatment Of Multiple Myeloma: Current Management And New ApproachesGibson, John; Ho, Phoebe (Joy); Joshua, Douglas; Central Clinical School: Medicine; Central Clinical School: Medicine; Central Clinical School: MedicineTreatment Of Multiple Myeloma: Current Management And New Approaches, American Journal of Cancer, vol.3,(1),2004,pp 47-66
2006The use of thalidomide in myeloma therapy as an effective anticancer drug.Gibson, John; Ho, Phoebe (Joy); Joshua, Douglas; Sze, Daniel; Brown, Richard P C; Yang, S; Central Clinical School: Medicine; Central Clinical School: Medicine; Central Clinical School: Medicine; PharmacyThe use of thalidomide in myeloma therapy as an effective anticancer drug., Current Cancer Drug Targets, vol.6,(4),2006,pp 325-331